| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BIO Stock Overview
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America.
Bio-Rad Laboratories, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$548.74 |
| 52 Week High | US$832.70 |
| 52 Week Low | US$462.61 |
| Beta | 0.95 |
| 1 Month Change | 12.46% |
| 3 Month Change | 9.29% |
| 1 Year Change | -29.49% |
| 3 Year Change | 67.55% |
| 5 Year Change | 158.32% |
| Change since IPO | 10,030.58% |
Recent News & Updates
Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M
Bio-Rad Labs press release (NYSE:BIO): Q2 Non-GAAP EPS of $3.38 beats by $0.67. Revenue of $691.1M (-3.5% Y/Y) beats by $26.5M. For the full-year 2022, the company now anticipates non-GAAP currency-neutral revenue growth to be at the high end of the prior 1.0 to 2.0 percent guidance, with Covid-related revenue expected to be about $93 million versus approximately $70 million previously.
Shareholder Returns
| BIO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 1.7% | 1.9% | 3.2% |
| 1Y | -29.5% | -19.8% | -10.1% |
Return vs Industry: BIO underperformed the US Life Sciences industry which returned -19.8% over the past year.
Return vs Market: BIO underperformed the US Market which returned -10.1% over the past year.
Price Volatility
| BIO volatility | |
|---|---|
| BIO Average Weekly Movement | 5.6% |
| Life Sciences Industry Average Movement | 11.0% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BIO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: BIO's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 7,900 | Norman Schwartz | https://www.bio-rad.com |
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.
Bio-Rad Laboratories, Inc. Fundamentals Summary
| BIO fundamental statistics | |
|---|---|
| Market Cap | US$16.15b |
| Earnings (TTM) | -US$1.94b |
| Revenue (TTM) | US$2.87b |
5.7x
P/S Ratio-8.4x
P/E RatioIs BIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO income statement (TTM) | |
|---|---|
| Revenue | US$2.87b |
| Cost of Revenue | US$1.21b |
| Gross Profit | US$1.66b |
| Other Expenses | US$3.61b |
| Earnings | -US$1.94b |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -65.41 |
| Gross Margin | 57.92% |
| Net Profit Margin | -67.66% |
| Debt/Equity Ratio | 13.3% |
How did BIO perform over the long term?
See historical performance and comparison